Listing of Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

1. (Cancelled)

2. (Currently Amended) A compound of formula (I),



(I)

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein

R^1 is C_{1-6}alkyl;

R^2 is hydrogen or hydroxy or taken together with R^4 may form =O;

R^4 is hydrogen, C_{1-6}alkyl, furanyl, pyridinyl, arylC_{1-6}alkyl or  ;

n is 0 or 1;

X is N or CR^5, wherein R^5 is hydrogen;

R^3 is -$(CH_2)_s$- NR^6R^7 ~~a radical selected from (a-1), (a-2) or (a-3)~~ or is ~~a group of formula (b-1) i.e.~~ –Z-;

s is 0, 1 or 2;

R^6 is –CHO, C_{1-6}alkyl, piperidinylC_{1-6}alkyl, arylcarbonylpiperidinylC_{1-6}alkyl or arylC_{1-6}alkyl(C_{1-6}alkyl)aminoC_{1-6}alkyl;

R^7 is hydrogen or C_{1-6}alkyl;

R^8 is C_{1-6}alkyl; when R^3 is ~~a group of formula (b-1)~~ –Z-, then Z is a heterocyclic ring system selected from (c-2) or (c-4)~~;~~ :

(c-2)



(c-4)

and each R^{10} independently is hydrogen, C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkylamino, with the proviso that when n is 0, X is N, R^2 is hydrogen, R^3 is a group of formula (b-1), Z is the heterocyclic ring system (c-2) or (c-4) wherein said heterocyclic ring system Z is attached to the rest of the molecule with a nitrogen atom, and R^{10} is hydrogen; then R^4 is other than hydrogen, C_{1-6}alkyl or pyridinyl.

.

3. (Currently Amended) A compound according to claim 2 ~~1~~ wherein n is 0; X is N or CR^5, wherein R^5 is hydrogen; R^1 is C_{1-6}alkyl; R^2 is hydrogen or hydroxy or taken together with R^4 may form =O; R^3 is a radical selected from (a-1) or (a-2); s is 0 or 1; R^6 is –CHO or C_{1-6}alkyl; and R^4 is hydrogen, C_{1-6}alkyl or



.

4. (Previously Presented) A compound selected from the group consisting of:

 compound 1	 compound 5
 compound 7	 compound 3
 compound 17	

and the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.

5. (Cancelled)

6. (Currently Amended) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 2 ~~1~~.

7. -9. (Cancelled).

10. (Currently Amended) A method for enhancing the effectiveness of chemotherapy comprising administration of a compound according to claim 2 ~~1~~, in a therapeutically effective amount so as to increase sensitivity of cells to chemotherapy, prior to administration of said chemotherapy .

11. (Currently Amended) A method for enhancing the effectiveness of radiotherapy comprising administration of a compound according ~~accordning~~ to claim 2 ~~1~~, in a therapeutically effective amount so as to increase sensitivity of cells to ionizing radiation, prior to administration of said radiotherapy

12. (Currently Amended) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of formula (I) according to Claim 2.



~~the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein~~

~~n is 0, 1 or 2;~~

~~X is N or CR^5, wherein R^5 is hydrogen or taken together with R^1 may form a bivalent radical of formula -CH=CH-CH=CH-;~~

~~R^1 is C_{1-6}alkyl or thienyl;~~

~~R^2 is hydrogen or hydroxy or taken together with R^3 or R^4 may form =O;~~

~~R^3 is a radical selected from~~

~~$-(CH_2)_s-NR^6R^7$ (a-1),~~

~~$-O-H$ (a-2),~~

~~$-O-R^8$ (a-3),~~

~~$-S-R^9$ (a-4), or~~

~~$-C\equiv N$ (a-5),~~

~~wherein~~

~~s is 0, 1, 2 or 3;~~

~~R^6 is -CHO, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyl, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkylcarbonylaminoC_{1-6}alkyl, piperidinylC_{1-6}alkylaminocarbonyl, piperidinyl, piperidinylC_{1-6}alkyl, piperidinylC_{1-6}alkylaminocarbonyl, C_{1-6}alkyloxy, thienylC_{1-6}alkyl, pyrrolylC_{1-6}alkyl, arylC_{1-6}alkylpiperidinyl, arylcarbonylC_{1-6}alkyl, arylcarbonylpiperidinylC_{1-6}alkyl, haloindozolylpiperidinylC_{1-6}alkyl, or arylC_{1-6}alkyl(C_{1-6}alkyl)aminoC_{1-6}alkyl;~~

~~R^7 is hydrogen or C_{1-6}alkyl;~~

~~R^8 is C_{1-6}alkyl, C_{1-6}alkylcarbonyl or di(C_{1-6}alkyl)aminoC_{1-6}alkyl; and~~

~~R^9 is di(C_{1-6}alkyl)aminoC_{1-6}alkyl;~~

~~or R^3 is a group of formula~~

~~$-Z$ (b-1),~~

~~wherein~~

~~Z is a heterocyclic ring system selected from~~



(c-1) (c-2) (c-3) (c-4)



(c-5) (c-6)

~~wherein each R^{10} independently is hydrogen, C_{1-6}alkyl, aminocarbonyl, hydroxy,~~



~~C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkylamino, arylC_{1-6}alkyl, di(phenylC_{2-6}alkenyl), piperidinylC_{1-6}alkyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkylC_{1-6}alkyl, aryloxy(hydroxy)C_{1-6}alkyl, haloindazolyl, arylC_{1-6}alkyl, arylC_{2-6}alkenyl, morpholino, C_{1-6}alkylimidazolyl, or pyridinylC_{1-6}alkylamino;~~

~~R^4 is hydrogen, C_{1-6}alkyl, furanyl, pyridinyl, arylC_{1-6}alkyl or~~  ;

~~aryl is phenyl or phenyl substituted with halo, C_{1-6}alkyl or C_{1-6}alkyloxy.~~

13. (Currently Amended) A process for preparing a compound as claimed in claim 2 ~~1~~, comprising: a) hydrolysis of intermediates of formula (VIII),



(VIII) (I)

b) cyclization of intermediates of formula (X),



(X) (I-j)

or c) condensation of an ortho-benzenediamine of formula (XI) with an ester of formula (XII) wherein R^h is C_{1-6}alkyl, into compounds of formula (I), wherein X is N, herein referred to as compounds of formula (I-i),



(XI) (XII) (I-i)

14. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 2.

15. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 3.

16 (Previously Presented)A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 4.

17. (Cancelled)

18. (Previously Presented) A method for enhancing the effectiveness of chemotherapy comprising administration of a compound according to claim 2, in a therapeutically effective amount so as to increase sensitivity of cells to chemotherapy, prior to administration of said chemotherapy .

19. (Previously Presented) A method for enhancing the effectiveness of radiotherapy comprising administration of a compound according ~~accordning~~ to claim 2, in a therapeutically effective amount so as to increase sensitivity of cells to ionizing radiation, prior to administration of said radiotherapy.

20. (Cancelled)

21. (Previously Presented) A method for enhancing the effectiveness of chemotherapy comprising administration of a compound according to claim 3, in a therapeutically effective amount so as to increase sensitivity of cells to chemotherapy, prior to administration of said chemotherapy .

22. (Previously Presented) A method for enhancing the effectiveness of radiotherapy comprising administration of a compound according ~~accordning~~ to claim 3, in a therapeutically effective amount so as to increase sensitivity of cells to ionizing radiation, prior to administration of said radiotherapy.

23. (Cancelled)

24. (Previously Presented)A method for enhancing the effectiveness of chemotherapy comprising administration of a compound according to claim 4, in a therapeutically effective amount so as to increase sensitivity of cells to chemotherapy, prior to administration of said chemotherapy .

25. (Previously Presented) A method for enhancing the effectiveness of radiotherapy comprising administration of a compound according ~~accordning~~ to claim 4, in a therapeutically effective amount so as to increase sensitivity of cells to ionizing radiation, prior to administration of said radiotherapy.

26 (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 2.

27 (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 3.

28 (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 4.

29.-30. (Cancelled)